(Q44079527)

29 November 2017

title

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours (English)

1 reference

29 November 2017

0 references

1 reference

Crul M

1

1 reference

29 November 2017

Rosing H

2

1 reference

29 November 2017

de Klerk GJ

3

1 reference

29 November 2017

Dubbelman R

4

1 reference

29 November 2017

Traiser M

5

1 reference

29 November 2017

Reichert S

6

1 reference

29 November 2017

Knebel NG

7

1 reference

29 November 2017

Schellens JH

8

1 reference

29 November 2017

Beijnen JH

9

1 reference

29 November 2017

ten Bokkel Huinink WW

10

1 reference

29 November 2017

publication date

1 August 2002

1 reference

European Journal of Cancer

29 November 2017

published in

1 reference

29 November 2017

volume

38

1 reference

29 November 2017

issue

12

1 reference

29 November 2017

page(s)

1615-1621

1 reference

Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Antitumoral activity of alkylphosphocholines and analogues in human leukemia cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Effect of lipid derivatives on invasion in vitro and on surface glycoproteins of three rodent cell types

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Three paths to stress relief

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Metabolism of ether phospholipids and analogs in neoplastic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

D-21266, a new heterocyclic alkylphospholipid with antitumour activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Quantification of perifosine, an alkylphosphocholine anti-tumour agent, in plasma by pneumatically assisted electrospray tandem mass spectrometry coupled with high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

Clinical evaluation of biologically targeted drugs: obstacles and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900127-2

7 January 2021

10.1016/S0959-8049(02)00127-2

Identifiers

DOI

1 reference

29 November 2017

1 reference